Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*Andreas Wollenberg, Norito Katoh, Hidehisa Saeki et al.|British Journal of Dermatology|2020Cited by 590
Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis FoundationVipawee S. Chat, April W. Armstrong, Christoph T. Ellebrecht et al.|Journal of the American Academy of Dermatology|2024Cited by 19
Dermatologic Procedures for the Treatment of Seborrheic Dermatitis.Dana Jaalouk, Naiem T. Issa, Anika Pulumati et al.|PubMed|2024Cited by 2
Consensus Statements on the Use of Novel Formulations of Isotretinoin: A Modified Delphi ProcessPaige Kingston, April W. Armstrong, Leon Kircik et al.|Journal of Drugs in Dermatology|2024Cited by 0